A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06619522
Phase
PHASE2
Status
Withdrawn

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    Given orally
  • INCB57643 — DRUG
    Given orally

Study Details

To assess INCB05643 + ruxolitinib JAKi-naive patients with myelofibrosis

Key Dates

First listed
Oct 1, 2024
Start date
Sep 11, 2024
Status verified
May 2025
Primary completion
May 9, 2025
Completion
May 9, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: INCB+ R

Primary Outcome Measure

Safety and Adverse Events (AEs). Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: Through study completion; an average of 1 year ]

Related Studies